Clinical
RSSArticles
-
Age Drives Stroke Risk in Atrial Fibrillation
Among patients with newly diagnosed atrial fibrillation age 66-74 years without other CHA2DS2-VASc risk factors for thromboembolism, the older they are in this age range, the more likely they are to experience a stroke. -
Time of the Essence with Dapagliflozin for Heart Failure
By adding dapagliflozin to maximally tolerated standard therapy for heart failure with reduced left ventricular ejection fraction, researchers noted the reduction in mortality and recurrent heart failure began within one month of starting this therapy. -
What Form of Heart Block?
Does the rhythm in the figure represent Mobitz II second-degree AV block, complete AV block, or Wenckebach? Does the patient need a pacemaker? -
Dapagliflozin Tablets (Farxiga)
Dapagliflozin can be prescribed to lower the risk of hospitalization for heart failure in adults with chronic kidney disease at risk for progression, end-stage kidney disease, cardiovascular death, and sustained estimated glomerular filtration rate decline. -
Loneliness and Type 2 Diabetes Incidence
Loneliness appears to be an independent risk factor for type 2 diabetes, although further research to identify the causal relationship between loneliness and type 2 diabetes development is needed. -
The Cost-Effectiveness of HPV Vaccination for Adults Age 30 to 45 Years
Researchers found extending the upper limit of HPV vaccination to age 30 to 45 years is not cost-effective. -
Antibiotic Therapy: How Long Is Long Enough?
The CDC and the American College of Physicians have provided advice on the best practice regarding the duration of antibiotic therapy for several common infections. -
HHS Expands Mental Health Services Access for Young Patients
Agency designates funding for existing program that promotes behavioral health integration into pediatric primary care using telehealth. -
Prophylaxis for Tuberculosis in Patients with Myasthenia Gravis
In this observational study from an area with a high rate of endemic tuberculosis (TB), prophylactic treatment of TB was appropriate in those treated with high doses of prednisone and evidence of prior TB infection.
-
Long-Term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality
Cholinesterase inhibitors are one of the few drug classes approved by the Food and Drug Administration for the treatment of patients with Alzheimer’s disease. This study shows a long-term benefit in slowing the decline of cognition, as measured by the Mini-Mental State Exam, but it is unclear if there is any benefit in quality of life.